GlassScriptPhysician profile
Laura Baehner
NPI 1003990516
$2,716.76
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $748 · 2023: $1,309 · 2024: $660.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,906 · Education: $62.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,906.31 |
| Education | $62.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $477.45 | 2022-2024 | Caplyta |
| Janssen Pharmaceuticals, INC | $343.43 | 2022-2024 | Invega Sustenna, Spravato |
| Otsuka America Pharmaceutical, INC. | $312.89 | 2022-2024 | Abilify Asimtufii, Rexulti, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $247.36 | 2022-2024 | Uzedy, Austedo Xr, Austedo |
| Abbvie INC. | $204.65 | 2022-2024 | Vraylar |
| Axsome Therapeutics, INC. | $177.08 | 2023-2024 | Auvelity |
| Alkermes, INC. | $175.40 | 2022-2024 | Aristada, Lybalvi |
| Corium, LLC | $166.48 | 2023-2024 | Azstarys, Azstarys |
| Lundbeck LLC | $151.64 | 2022-2023 | Rexulti |
| Neurocrine Biosciences, INC. | $135.92 | 2022-2024 | Ingrezza |
| Ironshore Pharmaceuticals INC. | $133.10 | 2022-2024 | Jornay Pm |
| Indivior INC. | $102.62 | 2023 | Perseris |
| Sunovion Pharmaceuticals INC. | $88.74 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Baehner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.